Pulmonary Arterial Hypertension
Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ociated with connective tissue diseases) in patients with WHO Functional Cl III-IV symptoms to improve exercise capacity.
Renal Dialysis
Epoprostenol is indicated for the use in haemodialysis in emergency situations when use of heparin carries a high risk of causing or exacerbating bleeding or when heparin is otherwise contraindicated.
Name | Description |
---|---|
Pharma licensing | Out-licensing (offer) |